Impact of Implementing Alternative Human Papillomavirus (HPV) Vaccination Strategies in Kenya: A Modeling Study
MDM Policy & Practice · 2026-01 · 11 (1)
DOI: 10.1177/23814683261456695 ↗Kurz gefasst
Fachartikel in der Zeitschrift MDM Policy & Practice, online erschienen am 29.06.2026. Verfasst von Valerian Mwenda und 4 weiteren Autor:innen. Beteiligte Einrichtung: ThinkWell, Nairobi, Kenya. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bill and Melinda Gates Foundation, gavi alliance, vaccine impact modelling consortium.
Abstract (Originalsprache)
Background
Implementation delays reduce population-level effects of evidence-based interventions. We conducted a modeling study to estimate the effect of priority policy decisions on a human papillomavirus (HPV) vaccination program in Kenya.
Methods
We used a static cohort model to estimate the health effects and costs of introduction and 1-dose switch delays, switching to nonavalent vaccine (9vHPV), supply disruptions, and various scale-up scenarios. Costs were evaluated from the health system perspective. We estimated cervical cancer cases, deaths, disability-adjusted life-years (DALYs), and program and health care costs.
Results
Compared with no vaccination, maintaining current program performance would avert approximately 173,000 (95% UI: 149,000–191,000) cases and 2.7 (2.3–3.0) million DALYs across 2019 to 2100. A gradual scale-up of the current 2-dose quadrivalent vaccine (4vHPV) program would avert an additional 16,000 (14–18,000) cases (9%), increasing to 33,000 (28–37,000) cases (19%) if a multiage catchup is implemented in 2030. Accelerated scale-up of 1-dose bivalent vaccine (2vHPV) would avert 184,000 (164–199,000) cases and 3.0 (2.6–3.2) million DALYs, compared with no vaccination; translating to an additional 11,000 (2–17,000) cases averted (6%) compared with maintaining a 2-dose strategy, but at lower program ($81 million vs $76 million) and treatment costs ($2.09 billion vs $2.07 billion). HPV vaccination introduction in 2015 rather than 2019 would have averted an additional 74,000 (43%) cases. Annual vaccine supply disruptions translates to less than 9,000 (200–16,000) cases (5%) and 212,000 (74–305,000) DALYs averted (7%) compared with a 1-dose strategy. A 1-dose 9vHPV strategy would have more health benefits and save additional treatment costs compared with a 1-dose 2vHPV vaccine.
Conclusions
Prompt 1-dose switch and rapid scale-up and adoption of a 9vHPV program should be priority policy decisions for Kenya.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- ThinkWell, Nairobi, Kenya.
- National Cancer Control Program, Ministry of Health, Nairobi, Kenya.
- National Vaccines and Immunization Program, Ministry of Health, Nairobi, Kenya.
- Department of Global Health, Boston University School of Public Health, Boston, MA, USA.
ORCID-Profile: Valerian Mwenda, Allison Portnoy
Förderung
- Bill and Melinda Gates Foundation
- gavi alliance
- vaccine impact modelling consortium
Zitieren
APA
Mwenda, V., Bor, J. P., Jalang'o, R., Musuva, A., & Portnoy, A. (2026). Impact of Implementing Alternative Human Papillomavirus (HPV) Vaccination Strategies in Kenya: A Modeling Study. MDM Policy & Practice, 11(1). https://doi.org/10.1177/23814683261456695
Vancouver
Mwenda V, Bor JP, Jalang'o R, Musuva A, Portnoy A. Impact of Implementing Alternative Human Papillomavirus (HPV) Vaccination Strategies in Kenya: A Modeling Study. MDM Policy & Practice. 2026;11(1). doi:10.1177/23814683261456695
BibTeX
@article{Mwenda2026,
author = {Mwenda, Valerian and Bor, Joan-Paula and Jalang'o, Rose and Musuva, Anne and Portnoy, Allison},
title = {Impact of Implementing Alternative Human Papillomavirus (HPV) Vaccination Strategies in Kenya: A Modeling Study},
journal = {MDM Policy & Practice},
year = {2026},
volume = {11},
number = {1},
doi = {10.1177/23814683261456695}
}
EUVIMED